Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer

被引:46
|
作者
Kantoff, PW
Halabi, S
Farmer, DA
Hayes, DF
Vogelzang, NA
Small, EJ
机构
[1] Dana Farber Canc Inst, Dept Adult Oncol, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[2] Duke Univ, Med Ctr, Ctr Stat, Canc & Leukemia Grp B, Durham, NC USA
[3] Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA
[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[5] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
关键词
D O I
10.1200/JCO.2001.19.12.3025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the prognostic significance of reverse transcriptase polymerase chain reaction (RT-PCR) detection of prostate-specific antigen (PSA) mRNA in the blood of men with hormone-refractory prostate cancer (HRPC). Patients and Methods: Peripheral blood was obtained from 193 men enrolled on Cancer and Leukemia Group B Study 9480, a prospective randomized comparison of three doses of suramin. RNA was isolated from the samples and assayed for the presence of PSA transcripts by RT-PCR. Results: RNA could be isolated in 156 (83%) of samples. PSA transcripts as measured by RT-PCR were detectable in 75 (48%) of the 156 patients. The median survival far those patients in whom no transcripts were detectable was 18 months (95% confidence interval [CI], 14 to 22 months) compared with 13 months (95% CI, 11 to 15 months) (P = .004) for those in whom transcripts were detectable. In a multivariate analysis in which other factors predictive of survival were used, RT-PCR for PSA provided independent prognostic information. Conclusion: RT-PCR for PSA predicts survival duration in a population of men with HRPC. J Clin Oncol 19:3025-3028. (C) 2001 by American Society of Clinical Oncology.
引用
收藏
页码:3025 / 3028
页数:4
相关论文
共 50 条
  • [21] PROSTATE-SPECIFIC ANTIGEN AS A MEASURE OF DISEASE OUTCOME IN METASTATIC HORMONE-REFRACTORY PROSTATE-CANCER
    KELLY, WK
    SCHER, HI
    MAZUMDAR, M
    VLAMIS, V
    SCHWARTZ, M
    FOSSA, SD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) : 607 - 615
  • [22] Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer
    Wehbe, TW
    Stein, BS
    Akerley, WL
    [J]. MAYO CLINIC PROCEEDINGS, 1997, 72 (10) : 932 - 934
  • [23] Economic impact of prostate-specific antigen doubling time in patients with hormone-refractory prostate cancer
    Mulani, P
    Botteman, M
    Hay, JW
    Cifaldi, M
    [J]. VALUE IN HEALTH, 2005, 8 (03) : 346 - 346
  • [24] The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: A comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer
    Pfitzenmaier, Jesco
    Ellis, William J.
    Hawley, Sarah
    Arfman, Edward W.
    Klein, Jeffrey R.
    Lange, Paul H.
    Vessella, Robert L.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2007, 25 (03) : 214 - 220
  • [25] Detection of circulating cells in prostatic cancer by reverse transcriptase-polymerase chain reaction of prostate specific antigen and prostate specific membrane antigen
    Kabay, Sahin
    Tefekli, Ahmet Hamdi
    Yucel, Mehmet
    Ustuner, M. Cengiz
    Hatipoglu, Namik Kemal
    Muslumanoglu, Ahmet Yaser
    [J]. CENTRAL EUROPEAN JOURNAL OF UROLOGY, 2009, 62 (01) : 21 - 24
  • [26] ENHANCED REVERSE-TRANSCRIPTASE POLYMERASE CHAIN-REACTION FOR PROSTATE-SPECIFIC ANTIGEN AS AN INDICATOR OF TRUE PATHOLOGICAL STAGE IN PATIENTS WITH PROSTATE-CANCER
    KATZ, AE
    DEVRIES, GM
    BEGG, MD
    RAFFO, AJ
    CAMA, C
    OTOOLE, K
    BUTTYAN, R
    BENSON, MC
    OLSSON, CA
    [J]. CANCER, 1995, 75 (07) : 1642 - 1648
  • [27] MOLECULAR STAGING OF PROSTATE-CANCER .2. A COMPARISON OF THE APPLICATION OF AN ENHANCED REVERSE-TRANSCRIPTASE POLYMERASE CHAIN-REACTION ASSAY FOR PROSTATE-SPECIFIC ANTIGEN VERSUS PROSTATE-SPECIFIC MEMBRANE ANTIGEN
    CAMA, C
    OLSSON, CA
    RAFFO, AJ
    PERLMAN, H
    BUTTYAN, R
    OTOOLE, K
    MCMAHON, D
    BENSON, MC
    KATZ, AE
    [J]. JOURNAL OF UROLOGY, 1995, 153 (05): : 1373 - 1378
  • [28] Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma
    Rozhansky, F
    Chen, MH
    Cox, MC
    Dahut, W
    Figg, WD
    D'Amico, AV
    [J]. CANCER, 2006, 106 (01) : 63 - 67
  • [29] Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
    Smith, DC
    Dunn, RL
    Strawderman, MS
    Pienta, KJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) : 1835 - 1843
  • [30] Prostate-specific antigen doubling time: A potential surrogate end point in hormone-refractory prostate cancer
    Schmid, HP
    Semjonow, A
    Maibach, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1645 - 1646